Remoxy NDA Set For Q2 Following Positive Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Oradur technology could make the oxycodone product less susceptible to abuse and differentiate it in the market, Durect CEO Brown tells the DAILY.